Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2006-06-27
2006-06-27
Wilson, James O. (Department: 1623)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
C544S253000
Reexamination Certificate
active
07067662
ABSTRACT:
Compounds, compositions and methods that are useful in the treatment of inflammatory and immune conditions and diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of a chemokine receptor. The subject methods are useful for the treatment of inflammatory and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis and type I diabetes.
REFERENCES:
patent: 5202322 (1993-04-01), Allen et al.
patent: 5256667 (1993-10-01), Allen et al.
patent: 5719144 (1998-02-01), Hartman et al.
patent: 5756502 (1998-05-01), Padia
patent: 5869665 (1999-02-01), Padia
patent: 5908930 (1999-06-01), Dow
patent: 6140064 (2000-10-01), Loetscher et al.
patent: 6545005 (2003-04-01), Baxter et al.
patent: 6605632 (2003-08-01), Lesieur et al.
patent: 6794379 (2004-09-01), Medina et al.
patent: 2002/0169159 (2002-11-01), Medina et al.
patent: 2003/0134843 (2003-07-01), Lubisch et al.
patent: 2005/0085490 (2005-04-01), Wang et al.
patent: 0481 614 (1992-04-01), None
patent: WO92/01675 (1992-02-01), None
patent: WO99/58495 (1995-11-01), None
patent: WO97/04775 (1997-02-01), None
patent: WO98/13350 (1998-04-01), None
patent: WO98/26664 (1998-06-01), None
patent: WO01/16114 (2001-03-01), None
patent: WO01/16114 (2001-03-01), None
patent: WO01/19800 (2001-03-01), None
patent: WO01/19800 (2001-03-01), None
patent: WO01/30768 (2001-05-01), None
patent: WO01/62758 (2001-08-01), None
patent: WO01057038 (2001-08-01), None
patent: WO01/77087 (2001-10-01), None
patent: WO01/98278 (2001-12-01), None
patent: WO02/28831 (2002-04-01), None
patent: WO 2004/064741 (2004-08-01), None
patent: WO 2004/113335 (2004-12-01), None
Agostini, et al., 1998 “Involvement of the IP-10 Chemokine in Sarcoid Granulomatous Reactions”,J. Immunol. 161: 6413-6420.
Balashov et al., 1999 “CCR5+and CXCR3+T Cells are Increased in Multiple Sclerosis and Their Ligands MIP-1 α and IP-10 are Expressed in Demyelinating Brain Lesions,” Proc. Natl. Acad. Sci. USA, 96:6873-78.
Banker, et al., 1996 “Prodrugs”,Modern Pharmaceutics, 3ed Marcel Dekker, New York596.
Bowdish et al. 2003 “Evaluation of An Oral CXCR3 Antagonists in a Rat Model of the Acute Allograft Rejection”,The Journal of the Heart and Lung Associationvol. 22 Supplement 1 p. S162.
Carter, et al., 2002 “Chemokine Receptor Antagonism as an Approach to Anti-Inflammatory Therapy: ‘Just Right’ or Plain Wrong?”,Current Opin. Chem. Biol., 6: 510-525.
Cecil's Textbook of Medicine, 20thEdition, vol. 1 (a996), pp. 1004-1010 (1996).
Cecil's Textbook of Medicine, 20thEdition, vol. 2, pp. 1992-1996 (1996).
Chabrier et al. Pubmed Abstract 10442086, also cited as Cell. Mol. Life Sci. 55/8-9 1029-35 (1999).
Chiang et al., Pubmed Abstract 12898413, also cited as Planta Med., 69/7, 600-4, (2003).
J.T. Coyle et al., 1983 Science 219, 1184-90.
Fife et al., 2001 “CXCL10 (IFN-λ-Inducible Protein-10) Control of Encephalitogenic CD4+T Cell Accumulation in the Central Nervous System During Experimental Autoimmune Encephalomyelitis”,J. Immunol. 166: 7617-7624.
Gerard, et al., 2001 “Chemokines and Diseases”,Nature Immunology, 2(2): 108-115.
Goldbeerg et al., 2001 Pubmed Abstract 11437993, also cited as Neuropathol. Appl. Neurobiol. 27/2, 127-38.
Hancock et al., 2000 “Requirement of the Chemokine Receptor CXCR3 for Acute Allograft Rejection,”J. Exp. Med., 192(10):1515-19..
Hancock et al., 2001 “Donor-Derived IP-10 Initiates Development of Acute Allograft Rejection”,J. Exp. Med. 193: 975-980.
Liang, et al., 2000 “Identification and Characterization of a Potent Selective, and Orally Active Antagonist of the CC Chemokine Receptor-1”,The J.of Biol. Chem. .25(23): 19000-19008.
Liu et al., 2001 “Neutralization of the Chemokine CXCL10 Reduces Inflammatory Cell Invasion and Demyelination and Improves Neurological Function in a Viral Model of Multiple Sclerosis”,J. Immunol. 167: 4091-4097.
Melter et al., 2001“Expression of the Chemokine Receptor CXCR3 and Its Ligand IP-10 During Cardiac Allograft Rejection”,Circulation104: 2558-2564.
Onuffer, et al., 2002 “Chemokines, Chemokine Receptors and Small-Molecule Antagonists: Recent Developments”, Trends in Pharmacological Sciences 23(10): 459-467.
Padia, J.K., et al., “Design and synthesis of novel nonpeptide CCK-B receptor antagonists,” Bioorganic & Medicinal Chemistry Letters, Oxford, GB, vol 7, No. 7, Apr. 8, 1997, pp. 805-810.
Proudfoot, et al., 2003 “Strategies for Chemokine Antagonists as Therapeutics”,Seminars in Immunology. 15:57-65.
Qin et al., 1998 “The Chemokine Receptors CXCR3 and CCR5 Mark Subsets of T Cells Associated with Certain Inflammatory Reactions,”J. Clin. Invest. 101(4): 746-54.
Rabin et al., 1999 “Chemokine Receptor Responses on T Cells Achieved Through Regulation of Both Receptor Expression and Signaling,”The Journal of Immunology, 162: 3840-50.
Rottman et al., 2001 “Potential Role of the Chemokine Receptors CXCR3, CCR4, and the Integrin αEβ7 in the Pathogenesis of Psoriasis Vulgaris”,Lab. Invest. 81(3): 335-347.
Ruschpler et al., 2003 “Hign CXCR3 Expression in nSynovial Mast Cells Associated with CXCL9 and CXCL10 Expression in Inflammatory Synovial Tissues of Patients with Rheumatoid Arthritis”,Arthritis Res. Ther. 5: R241-R252.
Sasaki et al., Nov. 2002 “Blockade of CXCL10 Protects Mice From Acute Colitis and Enhances Crypt Cell Survival”,Eur. J. Immunol. 32: 3197-31205.
Shields, et al., 1999 “Chemokine and Chemokine Receptor Interactions Provide a Mechanism for Selective T Cell Recruitment to Specific Liver Compartments with Hepatitis C-Infected Liver”,J. Immunol. 163: 6236-6243.
Sorenson et al., 1999 “Expression of Specific Chemokines and Chemokine Receptors in the Central Nervous System of Multiple Sclerosis Patients”,J. Clinical Invest. 103: 807-815.
Uckun et al., 2001 “Structure Based Design of Novel Anticancer Agents”, Current Cancer Drug Targets, 1, 59-71.
Wells, et al., 1999 “Chemokine Receptors and Their Antagonists in Allergic Lung Disease”Inflamm. Res., 48: 353-362.
Wolff, Manfred E. “Burger's Medicinal Chemistry, 5ed Part I”, John Wiley & Sons, 1995, pp. 975-977.
Zhao et al., 2002 Pubmed Abstract 121133984, also cited as J. Immunol., 169/3 1556-60.
Huang Alan Xi
Johnson Michael G.
Li An-Rong
Liu Jiwen
Marcus Andrew P.
Amgen SF, LLC
Johnsen Jason H.
Jones Day
Wilson James O.
LandOfFree
CXCR3 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CXCR3 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CXCR3 antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3646552